Prothena to Report Second Quarter 2026 Financial Results on August 6
Stocks in this Quantisnow insightHealth Care
Historical context for PRTA
Across the 14 sessions after earlier PRTA headlines, the stock closed higher 8 times and lower 6 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PRTA | SPY |
|---|---|---|---|
| May 8, 2026 | Prothena Reports First Quarter 2026 Financial Results and Business Highlights | +2.0% | +0.8% |
| May 1, 2026 | Prothena to Report First Quarter 2026 Financial Results on May 7 | -3.8% | +0.3% |
| Apr 28, 2026 | Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy | +6.7% | -0.5% |
| Apr 13, 2026 | Prothena Announces Leadership Team Updates | -1.8% | +1.0% |
| Mar 23, 2026 | Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026 | +0.8% | +1.1% |
| Mar 10, 2026 | Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy | -0.4% | -0.2% |
Quantisnow market dataNASDAQ
PRTA
Prothena Corporation plc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for PRTA
Full PRTA profile on Quantisnow Follow PRTA and get a push notification the moment its next story breaks.